ArticleFrontiers in medicine2025
Development of a short-term prognostic model for hepatitis B-related acute-on-chronic liver failure in a dual-center cohort.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Acute-on-chronic liver failure (ACLF) is a severe clinical syndrome marked by rapid progression and high short-term mortality. In the Asia-Pacific region, where the hepatitis B virus (HBV) is endemic, HBV-related ACLF (HBV-ACLF) represents the most common subtype. The aim of this study was to develop and validate a concise and accurate nomogram for predicting 28-day mortality in patients with HBV-related ACLF. Methods: A total of 159 patients with HBV-ACLF were enrolled, including 113 in the training cohort and 46 in the validation cohort. Clinical characteristics, routine laboratory parameters, and inflammatory cytokine levels were collected. In the training cohort, least absolute shrinkage and selection operator (LASSO) regression was applied to select variables, followed by multivariate logistic regression to construct a nomogram model (ICI). Model performance was evaluated in both cohorts using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA), and compared with COSSH-ACLF II, CLIF-C ACLF, AARC, CLIF-OFs, MELD, and CTP scores. Results: LASSO regression identified ln(INR), ln(Cr), ln(WBC), and ln(IL-6) as candidate predictors. Multivariate logistic regression further confirmed that ln(INR), ln(Cr), and ln(IL-6) were independent risk factors. The new model (ICI) demonstrated good discriminative ability with an area under the receiver operating characteristic curve (AUC) of 0.826 in the training cohort and 0.814 in the validation cohort. Calibration analysis showed excellent consistency, and decision curve analysis (DCA) indicated that the ICI model provided higher net clinical benefit across different threshold probabilities. Furthermore, compared with traditional models, the ICI model exhibited significant advantages in terms of discriminative ability and clinical benefit. Conclusion: The newly developed model (ICI) showed superior predictive performance for short-term prognosis in patients with HBV-ACLF, outperforming conventional scoring systems. It is anticipated that the ICI model will serve as a valuable instrument in complementing the conventional scoring system for the HBV-ACLF population in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.